What happened

Shares of rare disease biopharma Horizon Pharma (NASDAQ:HZNP) surged over 13% today after the law firm of Green, Griffith successfully asserted one of the company's patents covering Pennsaid 2% against a generic challenge from Teva Pharmaceuticals. It's the company's top-selling drug, having generated about one-fifth of total revenue in the first half of 2017.

The news marks an important win in Horizon Pharma's multi-front battle against scores of generic challengers. The company has settled all other generic litigation for Pennsaid 2%, so the market is hoping this is the last. As of 3:08 p.m. EDT, the stock had settled to a 11.8% gain.

A man sitting against a wall, browsing on his laptop, as dollar bills fall around him.

Image source: Getty Images.

So what

Pennsaid 2% is a non-steroidal anti-inflammatory drug mostly used to treat pain from osteoarthritis, general pain, and migraines. It brought in $92.8 million in revenue in the first six months of 2017, which represented 18% of total revenue during that period.

While still an important contributor to Horizon Pharma's overall business, Pennsaid 2% revenue fell 27% year over year. The company said 77% of the decline was due to lower pricing this year, and SEC filings show most of the decline occurred in the second quarter of 2017. Why did the company lower pricing? Well, one primary reason was to maintain market share in case generic challengers proved successful.

There have been quite a few challengers in recent years, including Amneal, Actavis (now part of Teva Pharmaceuticals), Apotex, Teligent, Lupin, Taro Pharmaceutical, Perrigo, and Watson Laboratories. SEC filings as of August 10 show all have been settled -- except for the challenge from Teva Pharmaceuticals.

Now what

Most generic challenges have been settled in court such that each generic cannot enter the market until 2029 -- except in certain conditions. If that's also the case for the Teva Pharmaceutical litigation, then it's a pretty big win for Horizon Pharma. The drug company may be able to at least stop lowering drug prices and maintain current revenue levels.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.